GYRE THERAPEUTICS INC. - COMMON STOCK

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

31 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

27 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

17 Mar 2025 16:15:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

13 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

22 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

01 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

13 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

09 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

02 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

18 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

30 May 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

28 May 2024 16:05:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:10:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

26 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire